Abstract: Vascular anomalies are localized defects of morphogenesis that can affect lymphatic and blood vessels. They are generally called birthmarks, typically observed soon after birth and occurring in up to 10% of children. Based on their clinical and histological characteristics, they are classified into vascular tumours and vascular malformations. The most common malformations are venous malformations (VMs) resulting in chronic vascular diseases that can be associated with significant morbidity necessitating often demanding and repeating clinical management. The current treatment is based on surgical resection and sclerotherapy, which can be impossible due to the size or location of lesions or ineffective due to the regrowth of malformed vessels. Therefore, medical therapies for VMs are highly desired. Recent studies have identified genetic defects that result in the constantly active endothelial cell receptor tyrosine kinase TIE2/phosphoinositide 3-kinase PI3K signalling pathway as a frequent cause for VMs. The first treatment to inhibit this pathway with sirolimus indicated that molecular treatment can be effective against VMs. In addition, certain VM 'hotspot' mutations have been previously found in tumours, providing the rationale for the exploration and repurposing of existing and investigational cancer drugs for VMs. Finally, discoveries of molecular and cellular abnormalities that characterize a large proportion of VMs and the generation of pre-clinical VM mouse models provide the necessary basis for the development of the targeted molecular treatment strategies we discuss in this MiniReview.
Altered functions of the vasculature are involved in many common human diseases, such as growth of malignant tumours and metastasis, cardiovascular diseases, diabetes and retinopathies. Studies focusing on the principles of vascular development have revealed growth factor families and cellular signalling mechanisms that are critical for morphogenesis and homeostasis of blood and lymphatic vessels. These studies have identified the Ang/Tie system as a major endothelial cell (EC) signalling pathway consisting of angiopoietin ligands (Ang 1-4) and the Tie (Tie1 and Tie2) receptor tyrosine kinases [1, 2] . Gene-targeting experiments have indicated that the Ang/Tie signalling system is needed for physiological and pathological remodelling of both lymphatic and blood vessels in embryonic, postnatal and adult mice [1] . In humans, an altered expression of angiopoietins is implicated in many vascular diseases [2] , and loss-of-function mutations in genes encoding TIE2 and its activating ANG1 ligand have been shown to result in the defective growth of Schlemm's canal (a specific type of hybrid blood/lymphatic vessel for aqueous humour out-flow in the eye), causing increased intraocular pressure and primary congenital glaucoma in children [3, 4] . Clearly, identification of effective therapeutic means to modulate Ang/Tie signalling has a high clinical value, and drugs targeting this pathway are in clinical trials for cancer and neovascular eye diseases [2] .
Venous malformations (VMs) are the most common vascular malformations, with an estimated incidence of 1-2 per 10,000 [5] . VMs can cause significant morbidity due to pain, disfigurement and organ dysfunction. Due to poor understanding of pathological mechanisms underlying the development of VMs, therapies have long been limited to compression therapy and ablation of malformed veins by sclerotherapy and surgery. Recent genetic and molecular biology studies have made breakthroughs in unravelling the genetic, molecular and cellular alterations that characterize a large proportion of VMs; more than half of VMs are found to be positive for gain-of-function mutations in TIE2 [6] [7] [8] . In addition, activating mutations in PIK3CA -encoding the p110a catalytic subunit of the phosphoinositide 3-kinase PI3K -are found in about half of the TIE2 mutation-negative VMs [6, 7, 9, 10] . These data have explained the genetic cause for most VMs and have identified the endothelial TIE2-PI3K axis as a major VM-causing signalling pathway that has been further investigated in cell culture and mouse models [6, [9] [10] [11] [12] [13] . In this MiniReview, we summarize the recent findings on VM genetics and molecular pathology and discuss the advancements made in in vitro and VM pre-clinical models. These have yielded insightful data on the pathological mechanism of VMs and have also led to the development of the first evidencebased molecular therapies which have already shown preliminary efficacy in pre-clinical and clinical studies [9, 10, 13, 14] .
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Clinical Presentation and Current Treatment of VMs
VMs are localized, congenital lesions of distorted slow-flow venous-like vessels. They are predominantly located in the skin and mucosa, but can also be found in deeper structures such as muscles and internal organs [15] . Macroscopically, VMs appear as a bluish/purple, soft, compressible vascular mass [16] . In histology, VMs are characterized by venous-like vessels with enlarged, irregular lumens, flat EC lining, thick, poorly organized fibrotic extracellular matrix (ECM) and uneven smooth muscle cell (SMC) layering [6, 17, 18] . VMs are not considered to be proliferative lesions, but they do grow in proportion to the individual and never regress spontaneously [19] . Typically, the patient has a single lesion present at birth, but in a subset of patients, multiple separate lesions are observed [7, 20] . Nevertheless, malignant transformation has not been reported. VMs are also observed as a part of vascular anomaly syndromes (e.g. Klippel-Trenaunay syndrome) and in combination with lymphatic and/or capillary malformations [21] .
Symptoms of VMs vary depending on the anatomical location of the lesion. Common complaints are pain, swelling and disfigurement [16] . Diagnosis is usually made in early childhood based on symptoms, clinical findings and imaging data [22] . As the clinical presentation is highly variable, the treatment strategy should be carefully planned by an experienced multidisciplinary team on a case-by-case basis [23, 24] . Sclerotherapy is usually the first-line treatment for symptomatic VM. A sclerosing agent such as ethanol is percutaneously injected into the lumen of the affected vessel to cause EC destruction and shrinkage of the lesion, also resulting in inflammation and subsequent fibrosis [25] . Usually, multiple treatment sessions are needed to achieve adequate symptom relief [26] . In the case of superficial VM with clear margins, surgical resection may be the primary treatment, but more often surgery is performed after sclerotherapy if symptoms persist [23] . As limitations, surgical resection can be impossible due to the size or location of lesions, and current treatments are only rarely curative as malformed veins can seldom be removed or destroyed completely and they tend to recanalize and recur [26] . Medical therapies are thus needed to improve the treatment of VM patients.
Genetic Cause of VMs and Subtypes
Genetic studies have been pivotal in elucidating the pathogenic mechanisms of VMs. More than two decades ago, cutaneomucosal venous malformation (VMCM), a rare autosomal dominantly inherited form of VM, was found to be associated with a TIE2 missense mutation (from arginine to tryptophan at residue 849 in the kinase domain) that increased TIE2 kinase activity indicating a gain-of-function effect [17] . The first observation was followed by the identification of somatic TIE2 mutations in more common sporadic VMs some 10 years later [7] . It is noteworthy that while inherited mutations are found from blood DNA, somatic mutations are only detected in affected tissue with a relatively low allele frequency [6, 7] . More than 20 different TIE2 mutations (Table S1 ) have been described in the literature occurring alone or as double mutations in cis (in the same allele) in exons 15, 17, 22 and 23 encoding intracellular kinase, kinase insert and C-terminal tail domains ( fig. 1) . Collectively, the genetic data indicate that most TIE2 mutations are somatic and explain more than half of all VMs.
Recently, PIK3CA was identified as a second major gene mutated in VMs [6, 9, 10] . Physiological angiopoietin ligand-induced TIE2 activation triggers PI3K signalling, which in ECs is mainly mediated by PIK3CA [27] . In vitro studies have confirmed that mutations in these genes reside in a common signalling pathway [6] (fig. 1 ). Based on genetic data from studies where both genes were extensively sequenced, TIE2 mutations account for 56% and PIK3CA 22% of all VM cases (Table 1 and Table S1 ). The remaining 23% TIE2/PIK3CA mutation-negative VMs are likely caused by infrequent mutations in several different genes connected to PI3K and MAPK signalling pathways, as suggested by Castel et al. [9] . This study, using targeted exome sequencing of 341 cancer-associated genes, found solitary VM cases with mutations in GNAQ, NF1, MAP2K1, MAP3K1, AKT2, AKT3 and IRS2 alone or in combination with a TIE2 or PIK3CA mutation. It is noteworthy that in only one case, a mutation in both TIE2 and PIK3CA has been reported in combination [9] .
Comprehensive clinical and genetic characterization has revealed distinct subtypes of VMs with differential clinical presentation and pattern of genetic mutations [6] [7] [8] 17, 20, 28] . Among the subtypes, sporadic unifocal VM where the patient has a single VM lesion without a family history is by far the most common form caused by either TIE2 or PIK3CA mutations. In a large cohort of 130 unifocal VM patients, it was reported that 59 of 80 (73.8%) TIE2 mutation-positive patients harboured the c.2740C>T (L914F) mutation, the most frequent TIE2 mutation reported in the literature overall and found iñ 28% of all VMs [6] (Table S1 ). Twenty-five of 27 (92.6%) PIK3CA-positive VMs had mutations causing amino acid changes E542K, E545K or H1047R, which are also frequently found in cancer and other PIK3CA-associated malformation/ overgrowth syndromes [29, 30] . Although TIE2 and PIK3CA are in the same pathway, some gene-specific effects may be present in unifocal VMs. For example, PIK3CA mutationpositive VMs were noted as more deeper lesions and not extending into the skin, in contrast to common TIE2 mutationpositive VMs. In addition, TIE2 and PIK3CA mutation-positive VM patients had significantly higher D-dimer levels compared with patients having no identified mutations in these two genes, and certain mutations were found to be enriched in histological VM subtypes [6] . When expressed in cultured ECs, both TIE2 and PIK3CA mutations activate Akt, but only TIE2 mutations cause phosphorylation of Erk1/2 and Stat1, suggesting some differences in the activation of downstream signalling [6, 12] . However, further studies are needed to reveal the significance of these observations. Rare familial VMCM patients have multifocal variable-sized VMs predominantly in the skin and mucosa [17, 28] . The most common inherited mutation in TIE2 is R849W (11 of 18 cases reported). Other mutations are reported as a single case each [17, 28, 31, 32] (Table 2) . Based on the current view, inherited TIE2 mutations are likely not able to cause VM lesions alone but need another genetic change. This is supported by the presence of somatic 'second hits' in TIE2 in lesions of VMCM patients, as a loss-of-function deletion mutation in trans (deleting a possibly protecting WT allele) or as a second missense mutation in cis [7, 20] , likely potentiating the gain-of-function effect of relatively weaker inherited mutations when compared to mutations found alone in sporadic VMs [11, 12] . On the other hand, TIE2-L914F, TIE2 double mutations or PIK3CA mutations have never been found as inherited, suggesting that they all are lethal in germline, as already shown for PIK3CA-H1049R using genetic mouse models [9, 33] .
Multifocal VMs can also occur sporadically, and they frequently associate with TIE2 double mutations. Soblet et al. [20] Table S1 ). Mutations induce ligand-independent tyrosine phosphorylation (P) and downstream activation of the PI3K/AKT signalling pathway. In TIE2 mutation-negative VMs, activating mutations are frequently found in PIK3CA encoding the catalytic subunit of PI3K [6, 9, 10] (Table S1 ). Biochemical and cell biological data show that TIE2 and PIK3CA participate in the same VM causative signalling pathway [6] . Some gene-specific effects may also exist. In addition to PI3K signalling, both in vitro and genetic data suggest the involvement of activation of MAPK, which may be important for some cellular abnormalities in VMs [9, 12] . Most potent inhibitors for VMs (sirolimus and alpelisib) are indicated. Rubber Bleb Nevus syndrome (BRBNS). Patients with BRBNS usually had a single large dominant lesion present at birth, but in contrast to unifocal VMs, the number of lesions increased with age, resulting in multiple smaller VMs, preferentially in the palms and soles. Importantly, patients with BRBNS also had gastrointestinal lesions and frequently needed iron supplementation due to bleeding complications. In the same study, six of 23 patients also had multiple VM lesions but lacked gastrointestinal VMs and did not present with dominant lesions or anatomical preference [20] . These individuals were classified under a diagnosis of multifocal sporadic VM (MSVM). While both groups had TIE2 double mutations, they differed in terms of mutational spectrum and acquisition of the mutations. Patients with BRBNS typically had somatic T1105N-T1106P double mutation, which was not detected in blood DNA. In contrast, MSVM patients most commonly had R915C combined with Y897C or L914F in cis. Interestingly, in three of six patients, R951C was also detected from blood DNA with a low allele frequency, suggesting that these patients are a mosaic for R915C, and a second mutation would be a somatic second hit needed for lesion formation reminiscent of inherited VMCM [7] . In contrast to TIE2, PIK3CA mutations have not been reported in VMCM, BRBNS or MSVM. With clinical and genetic data taken together, distinct presentations of VM diseases may exist with a differential mutation spectrum and acquisition sequence of mutations.
Whether specific mutations enriched in distinct clinical and genetic entities can cause specific cellular or molecular defects that may explain different phenotype presentations has been explored to a limited extent [20] .
Molecular and Cellular Pathology of VMs
The majority of VMs are due to gain-of-function somatic mutations in the genes encoding TIE2 or PIK3CA, resulting in chronic activation of the TIE2/PI3K/Akt signalling pathway ( fig. 1 ) [6, 7, 9, 10] . In addition, both VM EC transplantation studies and use of EC-specific Cre drivers together with inducible VM mutations have indicated that TIE2 or PIK3CA mutation in an EC compartment is sufficient for VM lesion formation [9, 10, 12, 13, 33] . Disease mechanisms downstream from a mutated TIE2/PIK3CA are not completely understood. However, several molecular and cellular dysfunctions have been identified that may have a role in the initiation, growth and maintenance of VM lesions ( fig. 2 ). These may affect EC intrinsic functions, EC-SMC interactions, perivascular ECM remodelling and venous specification [10] [11] [12] . Not all in vitro alterations have been confirmed in VM tissues, and cellular abnormalities observed on plastic dishes or in 3D fibrin gels are not necessarily directly comparable to the VM lesions in vivo. For translational studies, however, identification of quantifiable in vitro phenotypes due to increased TIE2/ PIK3CA signalling should provide feasible readouts for identification of novel molecular inhibitors able to normalize VM signalling. Common to all TIE2 mutations is an increase in ligand-independent TIE2 tyrosine phosphorylation (i.e. kinase activation). In cell culture models, the extent of TIE2 autophosphorylation is highly variable, however, and no correlation with severity of clinical phenotype can be made [7, 12, 20, 28] . Another common feature is altered trafficking and low plasma membrane translocation of TIE2 VM protein, which may hamper normal, ligand-regulated TIE2 functions and thus potentiate VM pathogenesis [7, 12] ( fig. 2C ). In addition to Akt, studies focusing on signalling pathway(s) downstream from mutations have revealed increased Erk1/2 phosphorylation in cell lysates. The MAPK inhibitor (PD98059) restored major features of VM ECs [12] , supporting the importance for MAPK signalling. Additional evidence for involvement of MAPK comes from genetic analysis of TIE2 and PIK3CA mutation-negative VMs that have indicated some sporadic mutations in the MAPK pathway [9] . On the other hand, in cultured ECs, PIK3CA mutations seem to mainly activate Akt and not MAPK but nevertheless lead to highly similar cellular phenotype compared with TIE2-VMs [6] . Currently, the exact importance of MAPK in VM pathogenesis and possible cooperation/crosstalk of the MAPK and PI3K signalling pathways in VMs is unclear.
Akt activation provides a strong cell survival signal that is also induced by ANG1-activated TIE2-WT [34] . Consistently, TIE2-VM mutations increase the viability of non-adhered ECs [20] and dominant-negative Akt inhibited pro-survival phenotype of TIE2-R849W in cultured ECs [18] . In addition, less apoptotic p53 staining was histologically observed in mutant ECs in VM lesions compared to TIE2-WT in a mouse transplantation model [12] . It has been proposed that an increase in Akt may support EC survival in SMC-deficient malformed veins [18] , but the importance of increased resistance to apoptosis for VMs is not established.
Vascular anomalies are classified into two main groups based on cellular proliferation: highly proliferating vascular neoplasms including hemangiomas and malformations, in the latter EC proliferation is not considered pathological [21] . On the other hand, as VMs are characterized by abnormally 3 Information ambiguous in [8] . 4 [85, 86] sequenced only exon 17 of TIE2, so the presence of other TIE2 mutation cannot be excluded.
enlarged vascular channels, it is reasonable to assume that increased EC proliferation has a role. However, in clinical VM biopsies, proliferation is not a prominent feature [35] [36] [37] [38] . In addition, TIE2-L914F increases the number of human umbilical vein ECs (HUVECs) by extending their lifespan rather than proliferation in vitro, and in the mouse transplantation model, no increase in EC proliferation was observed [11, 12] . On the other hand, VEGF-A-stimulated PIK3CA-VM-transduced ECs proliferated more than PIK3CA-WT ECs [33] and Pik3ca H1047R increased EC proliferation but not the rate of apoptosis in genetic mouse models [9, 10] . These discrepancies could be due to the different model systems and time points studied. It could be that VMs have an initial proliferative phase followed by slow growth in an established lesion where resistance to apoptosis maintaining ECs would be more important than proliferation. As VMs are typically present at birth, a developmental stage when ECs are more sensitive to respond to proliferative signalling may exist, which may depend on the presence of additional growth factors. Cell migration is another EC function predicted to be influenced by TIE2 mutations based on microarray transcriptome screening of TIE2-L914F-transduced HUVECs [11] . However, migration velocities are not increased based on an in vitro assay [20] .
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Venous malformation Histologically, VMs are characterized by defective SMC coverage around malformed veins. In lesions, SMCs are focally either absent or present as irregularly distributed clumps indicating that the EC-SMC interplay is impaired in VMs [6, 17] . The forkhead box protein O1 (FOXO1) transcription factor is negatively regulated by activated Akt [39] . As a consequence, FOXO1 target genes, implicated in vascular morphogenesis and remodelling, are downregulated in ECs expressing either TIE2 or PIK3CA mutations [6, 10, 11] . These include reduction in a potent vascular SMC attractant PDGF-B in VM mutant gene-transduced HUVECs, retinas of Pik3ca H1047R mice, biopsies from TIE2 mutation-positive VM lesions [10, 11] , and also serum samples from non-genotyped VMs [40] . Although not mechanistically yet proved, the decrease in PDGF-B could explain the defective SMC coverage characterizing the VM lesions. Another factor essential for SMC migration, differentiation and vascular stabilization is the transforming growth factor beta (TGF-b) [41] . VM tissue shows reduced expression of TGF-b compared to normal human skin [42, 43] . In another study, Xia et al. [44] observed that levels of miR-145 -a microRNA regulator of SMC differentiation and motility -correlate with TGF-b expression and low levels of aSMA + cell coverage in VM tissue. Interestingly, their levels were restored in human VM samples after sclerotherapy using bleomycin A5 and in HUVECs treated with bleomycin in vitro [42] [43] [44] . As TGF-b seemingly also composes a balancing partner for TIE2 activity [43, 45] , more thorough knowledge of its regulation and downstream signalling might offer a route to a better understanding of VM pathogenesis. At the cellular level, overexpression of TIE2 or PIK3CA VM mutations in HUVECs causes perturbation of the organized EC monolayer typical for TIE-WT ECs [6, 12] . Instead of a cuboidal, cobblestone-like phenotype, VM mutant cells are elongated and cross over each other with a fibroblastlike appearance. In TIE2-VM-transduced ECs, this results from the loss of ECM fibronectin (FN), which can be rescued with Erk1/2 inhibition (with PD98059) [12] . Loss of ECM FN and EC monolayer organization is common to all TIE2 and PIK3CA-VM mutations analysed [6, 12] . Interestingly, in PIK3CA-VM HUVECs, FN is lost without evident Erk1/2 activation [6] . On the other hand, in both TIE2-VM and PIK3CA-VM ECs, the PIK3CA inhibitor (alpelisib) could restore the EC monolayer organization and ECM FN, while Akt inhibition (with LY294002 or sirolimus) had no clear effect [6, 12] . Although altered morphology of mutant ECs observed in vitro does not have a directly comparable counterpart in vivo, transmission electron microscopy (TEM) analysis of VM tissues reveals uneven and discontinued endothelium, EC elongations and disorganized alignment of cytoskeletal filaments [12, 43] . Collectively, these observations suggest that altered ECM and cytoskeleton signalling may have a key role in VM pathogenesis and importantly serve as an easily observable parameter for EC normalization for in vitro studies. Abnormalities in EC-EC interactions may relate to reduced expression of adhesion proteins VE-cadherin and N-cadherin seen in VM tissue biopsies [43] .
As a prominent and consistent change in VM biopsies from patients and mouse transplantations, TEM has revealed abnormalities in perivascular ECM. These include structural changes in the basement membranes (BMs) and fibrillar collagen matrix, suggesting continuous remodelling [12, 43] . Interestingly, structurally aberrant ECM is accompanied by strong Fig. 2. (A) Endothelial angiopoietin/TIE/PI3K pathway regulates vascular morphogenesis and remodelling in normal development. EC-specific deletion of Pik3ca (encoding p110 catalytic subunit of PI3K) results in defective angiogenic sprouting and vascular remodelling [27] . Ang/Tie signalling is required for vascular remodelling in different vascular beds [1] . In the postnatal mouse retina model of angiogenesis, Tie2 is expressed more in venous than in arterial endothelial cells (ECs) to support newly formed veins via COUP transcription factor 2 (COUP-TFII) [58] . In addition, an excess of Tie2 activating ligand Ang1 stimulates capillary-to-venous remodelling [78] [79] [80] . EC to smooth muscle cell (SMC) signalling is also regulated by other signalling systems, including platelet-derived (PDGF) and transforming (TGF) growth factor families [81] . During vascular morphogenesis ECs, SMCs and interstitial cells secrete structural and matricellular proteins to form a basement membrane and fibrillar collagen matrix for signalling functions and structural support. The perivascular extracellular matrix (ECM) is remodelled as a response to different stimuli and involves proteolytic degradation, ECM deposition and regulation of gene expression in ECs, SMCs and fibroblasts. (B) Activating TIE2 and PIK3CA-VM mutations cause molecular and cellular dysfunctions that may disturb normal vascular development. In retrovirally transduced human umbilical vein ECs (HUVECs), TIE2-VM forms activate MAPK and Akt signalling pathways. Inhibition of Erk1/2 restores loss of ECM fibronectin (FN) and EC monolayer organization and normalizes the plasminogen (PA) activation system [12] . Increase in Akt signalling reduces EC secretion of SMC attractant PDGF-B in HUVECs and increases EC survival in vitro [11, 18] . In Pik3ca H1047R mouse models, Akt also increased EC proliferation [9, 10] and decreased expression of arteriovenous specification markers (COUP-TFII, Eph-B4 and Ephrin-B2) [10] . qPCR and immunostaining analysis of human VM tissues have revealed downregulated TGF-b, CCN2 and cadherins regulating ECM composition, SMC recruitment and EC-EC adhesion [42, 43] . Ultrastructural analyses of VM lesions in the VM mouse model [12] and patient biopsies [12, 43] showed a disorganized fibrillar collagen matrix and basement membrane (BM) abnormalities that may reflect increased in vitro expression of ADAMTS peptidases [11] and plasminogen activators (tPA, uPA) [6, 12] that degrade ECM proteins and activate matrix metalloproteinases for ECM remodelling. Fluid from VM lesions [52] and cultures of retrovirally transduced VM mutation HUVECs (J. Kangas and L. Eklund, unpublished) contain an increased amount of cell shed microparticles, whose importance for VM pathogenesis is currently unknown. (C) Schematic representation of TIE2-VM (left) and normal TIE2/ANG signalling (right) in ECs. In normal ECs, extracellular angiopoietin ligands induce TIE2 translocation and activation in specific subcellular domains in EC-EC and EC-ECM contact sites to regulate vascular stability and motility [82] [83] [84] . Several mechanisms have been identified in TIE2-VM protein trafficking that may hamper normal ligand-regulated TIE2 signalling in specific cell compartments. These include TIE2 intracellular retention, increased turnover rate, extracellular domain shedding, and incomplete translocation and activation in EC-EC junctions [12] . In contrast to angiopoietin ligand-regulated activation of TIE2-WT, TIE2-VM receptors are constantly phosphorylated (P) ligand-independently in abnormal subcellular compartments. Another mechanism that silences the normal TIE2 function in VMs is a somatic second-hit deletion mutation in a TIE2-WT allele in trans resulting in intracellular retention [7] . induction of pericellular proteolytic pathways in vitro: upregulated gene expression of the ADAMTS family of peptidases and plasminogen activation system (increase in tissue-and urokinase-type plasminogen activators, tPA and uPA, decrease in plasminogen activator inhibitor, PAI-1). These proteases can degrade many ECM and BM constituents and activate matrix metalloproteinases for ECM remodelling [6, 11, 12] . Finally, downstream from TGF-b, connective tissue growth factor 2 (CCN2), a matricellular protein regulating cell-ECM interplay, is downregulated. Low TGF-b/CCN2 has shown to be associated with a reduction in ECM and BM components such as FN, collagen I and laminins a3 and a5 [42] .
Taken together, SMC coverage and structural alterations in perivascular ECM may alter ECM to EC signalling and cell cytoskeleton, weaken the perivascular support in the vascular wall and contribute to lesion formation. The exact roles of increased EC's resistance to apoptosis and proliferation are currently not clear. As VMs are usually present congenitally, it could be that VMs are preferentially induced during a state in vascular development where the vessel structure and constituent cells are permissive to venous remodelling. On the other hand, in some cases, this hypothesis does not hold. For example, in BRBNS, new lesions seem to develop in adulthood and VM-like lesions can also be induced postnatally in a genetic mouse model [20, 33] .
VM Biomarkers
The recent characterization of TIE2 and PIK3CA mutationpositive in vitro EC models, VM mice and patients have increased the knowledge about VM pathophysiology and unravelled altered molecules that can potentially be used as biomarkers for VMs [6, [9] [10] [11] [12] [13] . A gene test for TIE2 and PIK3CA mutations is the most definite biomarker for VMs. The recurrent mutations cover a significant proportion (about 80%) of all VMs; however, sequencing currently requires a tissue biopsy for mutation detection. Whether the mutational status is clinically useful for predicting the response to a specific treatment modality remains to be studied. Of note, the gain-of-function mutation in TIE2 is thus far the only VMspecific molecular abnormality, while PIK3CA substitutions are also detected in cancers and overgrowth syndromes [29, 30, 46] .
In a blood coagulation reaction, thrombin converts fibrinogen to fibrin that is cleaved by plasmin in fibrinolysis, resulting in the formation of D-dimers as a fibrin degradation product. Unlike other vascular malformations, VMs are associated with localized intravascular coagulopathy, and patients often have elevated D-dimers and in severe cases low fibrinogen serum levels [6, 13, 40, [47] [48] [49] [50] [51] . D-dimer testing has shown to be useful to separate VMs from other vascular or lymphatic malformations which usually present with normal D-dimers [48, 50] . Interestingly, VM patients with identified TIE2 or PIK3CA mutations had high D-dimers when compared to patients with no detectable mutation in these genes [6] . The utilization of D-dimers and fibrinogen as serum biomarkers for VMs is further strengthened by the observation of strongly upregulated plasminogen/plasmin proteolytic activity in TIE2 and PIK3CA-VM mutation-transduced HUVECs [6, 12] . Interestingly, these in vitro studies suggest that a high serum level of D-dimers is not solely due to static blood flow in the lesions, but also to an intrinsic signalling defect in ECs due to constantly high TIE2/ PIK3CA activity.
Another potential biomarker that can be measured from the blood or serum is PDGF-B, which is consistently downregulated in different models and clinical samples, including VM mutant-transduced ECs, genetic VM mouse model, tissue biopsies and serum from VM patients [10, 11, 40] . It has also been recently shown that the peripheral blood of VM patients contains more cell-derived microparticles than similar samples of healthy controls [52] . The number of microparticles is higher if the sample is taken directly from the lesional fluid and correlates with the size of the lesion. In addition, the mRNA and microRNA content of these microparticles differs significantly from that of the healthy controls. The exact function or importance of microparticles is unknown, but they could represent the parent cell they are budded from and therefore provide a molecular readout of VM ECs [52] . ANG2, a context-dependent antagonistic ligand of TIE2 induced in vascular remodelling and EC activation, is another Akt/FOXO1-dependent gene strongly downregulated in VM HUVECs [6, 11] . In addition, other biomarkers whose use may be limited to in vitro tests include decreased ECM FN and activation status of Akt and Erk1/2 [12] . Further studies are needed to evaluate the utility of potential VM biomarkers, whether and how they could be potentially used in experimental and clinical settings to follow responses to treatment. As many observed changes are not specific to VMs, their use in diagnosis is likely limited.
Pre-Clinical Development of Molecular Treatment for VMs in Mouse Models
Both genetic-and EC transplantation-based mouse models for VMs have been developed [9, 10, 12, 13, 33] . Models have proven useful for the study of VM pathogenesis and molecular therapies ( fig. 3) . In the xenotransplantation model, HUVECs retrovirally transduced to overexpress mutated TIE2 forms were injected subcutaneously into immunocompromised mice, either as a suspension in matrigel or as EC spheroids in a matrigel/fibrin matrix [12, 13] . In the transplanted plugs, ECs form tubular structures that can connect to the host mouse vasculature to form VMs. VMs observed in the transplantation model are abnormally enlarged, slowflow, blood-filled channels with a continuous EC layer, patchy pericyte/SMC coverage and aberrant ECM, thus closely resembling the histopathology and defective blood flow of human VMs [12, 13] . The effects of the mechanistic target of rapamycin (mTOR) inhibitor sirolimus (also known as rapamycin) and TIE2 tyrosine kinase inhibitor (TIE2-TKI) were tested in the transplantation model using TIE2-L914F-expressing HUVECs [13] . In vitro sirolimus inhibited TIE2-L914F-induced Akt phosphorylation in HUVECs, and when injected intra-peritoneally, sirolimus was effective in reducing VM formation and stopping the growth of established lesions, but was not able to diminish established VMs. Surprisingly, TIE2-TKI was far less potent in treating VMs in this model, which is likely explained by the weak inhibition of TIE2-L914F by this inhibitor. In addition to the human EC-based transplantation model, PIK3CA mutations have been tested using allografting of vascular lesions isolated from Pik3-ca H1047R -CAG-CreER mice [9] . In this model, another mTOR inhibitor everolimus and PIK3CA inhibitor alpelisib (BYL719) were able to prevent VM growth with marked response observed with alpelisib and partial reduction with everolimus. The importance of high Akt signalling for vascular malformations has also been previously noticed when immortalized murine ECs overexpressing constitutively active myristoylated Akt formed VM-like lesions when transplanted into nude mice [53] . Genetic mouse models [9, 10, 33] for VMs are based on inducible Pik3ca gain-of-function mutation H1047R (either as allelic knock-in or in Rosa26 locus). Of note, H1047R is frequently found in VMs, but also in lymphatic malformations [29] and overgrowth syndromes [46] . Castillo et al. [10] used T-promoter-driven CreER and a suboptimal dose of 4-hydroxytamoxifen to induce a mosaic expression of Pik3-ca H1047R in embryonic mesoderm (MosMes-Pik3ca H1047R ), which gives rise to an EC lineage. This resulted in cutaneous and internal VMs, without apparent defects in other tissues. Pik3ca H1047R was further analysed in a postnatal retina model of angiogenesis using inducible, EC-specific Pdgfb-Cre [10] . This resulted in abnormally enlarged vascular structures, EC hyperplasia, impaired pericyte coverage and low expression of arteriovenous specification marker genes, but not increased angiogenic sprouting. The other genetic models were also based on inducible PIK3CA-H1047R mutation, but using a Rosa26 locus targeted allele [9, 33] . In this model, expression of mutant Pik3ca H1047R was induced either in endometrial epithelial cells and in some ECs in spine vasculature (by crossing with Sprr2f-Cre driver mouse line), ubiquitously in 6-to 8-week-old mice (CAG-CreER) and in developing vasculature (Tie2-Cre) [9] . Di Blasio et al. [33] similarly induced expression of Pik3ca H1047R using Tie2-Cre or in posterior leg vasculature using EC-specific inducible Cre (Cdh5-CreERT2) and local injection of 4-hydroxytamoxifen. These genetic models indicated that, depending on the extent of expression and age of induction, Pik3ca H1047R results in vascular dysmorphogenesis and formation of VMs that phenocopied characteristics of VMs observed in patients [9, 10, 33] . Collectively, both genetic-and transplantation-based models offer versatile tools to study the pathology of VMs, as well as the efficacy and safety of potential molecular therapies. Transplantation models allow analysis of localized lesions, which mimic somatic VMs in patients, are flexible for additional genetic modifications and feasible for screening of different VM mutations. The disadvantages of HUVEC-based models are that they use immunocompromised mice and retrovirally transduced ECs that overexpress mutant proteins and are 3 . In vivo models for VMs. In the VM transplantation model [12, 13] , retrovirally transduced human ECs stably expressing TIE2-VM mutations are transplanted into immunocompromised mice where they give rise to a network of vessels that connects to the host vasculature. The model recapitulates well VM phenotypes and mimics local subcutaneous somatic VM lesions. The disadvantage is that it uses immunocompromised mice and TIE2 overexpression. Also allograft studies using matrigel-embedded minced VM lesion material from a genetic Pik3ca-VM mouse has been used in pharmacological studies in an immunodeficient host [9] . Genetic models are based on floxed Pik3ca H1047R alleles induced at different development stages, either ubiquitously or conditionally in non-ECs and ECs, resulting in vascular dysmorphogenesis and development of VMs resembling human lesions [9, 10, 33] . No gene-targeted VM model based on TIE2 mutation has been published. (B) Example of clinical appearance of VM lesions in a tongue and (C) in a mouse EC transplantation assay that closely resemble each other. Panels (B) and (C) reprinted from [12] with permission of Oxford University Press.
anatomically artificial compared to genetic mouse models where lesions are present in native tissues.
Pharmacotherapy of VMs
Like many other rare diseases, investments needed for the development of drugs designed against VMs are higher than the possible profit from the markets, and therefore, it is unlikely that VMs will attract sufficient interest from pharmaceutical companies. Pathways upregulated in VMs, especially PI3K/Akt and MAPK, are extensively studied major culprits in cancer, and many experimental and clinically approved drugs targeting these pathways exist [54, 55] , thus making drug repurposing a logical strategy to develop pharmacotherapy for VMs (Table 3 ). Direct targeting of the chronically activated TIE2 or PIK3CA kinases using specific inhibitors to stop the pathological signalling should yield the best response. Unfortunately, drug compounds specifically inhibiting TIE2 or PIK3CA have not yet reached the clinic in any indication [2, 56] .
TIE2 inhibition has been tested in a mouse transplantation model of VM, but likely due to poor inhibition efficiency of the TIE2-TKI used, the results were only modest [13] . In postnatal and adult mice, TIE2 seems to have only a limited role in overall vascular homeostasis, as conditional knockout after birth leads to defects that seem to be mainly limited to Schlemm's canal of the eye, lymphatic capillaries of the corneal limbus [57] and postnatal mouse retina [58] . Inhibition of the mutated TIE2 in VMs could thus be possible without severly disrupting normal vascular functions. TIE2 inhibitors currently in pre-clinical and clinical trials are multikinase inhibitors targeting additional kinases such as PDGFRb, VEGFR and MAPKs [2] . Even though the inhibition of multiple targets in general would appear undesirable, the targeting of TIE2 and MAPKs signalling in combination could be beneficial in VMs, as Erk1/2-mediated signalling causes part of the TIE2 mutation-induced cellular dysfunctions in in vitro studies [12] . Perhaps the most significant limitation of targeting TIE2 is that it would likely be of no use in VMs caused by mutations in PIK3CA or other genes downstream of TIE2. In addition, TIE2 inhibition cannot be generalized to other vascular anomalies as TIE2 gain-of-function mutations have thus far only been found in VMs.
As TIE2 and its downstream target PIK3CA activate the same major pathway to cause VMs and mutations in these two genes account for three quarters of all VM cases, targeting PIK3CA should cover for the majority of patients [6] ( Table 1) . One potent drug for repurposing is alpelisib, a highly specific PIK3CA inhibitor currently in Phase I-III clinical trials for the treatment of various types of cancer as combination therapy [56, 59] . Alpelisib was able to efficiently inhibit Akt phosphorylation and normalize the phenotype of both TIE2-VM-and PIK3CA-VM-transduced HUVECs in vitro [6] and drastically diminish VM lesion growth in mice [9] . Importantly, alpelisib was also efficient in treating cutaneous VMs in mouse allotransplantation model when administered topically as a cream, a method which could be useful in limiting adverse effects of systemic PI3K-inhibition [9] . Alpelisib has not yet been tested clinically in VM, but a case report describes remarkably beneficial effects in two patients with rare, life-threatening overgrowth syndrome (CLOVES) caused by somatic PIK3CA mutations and affecting multiple tissue types including vasculature [60] .
By far the most advanced pharmacotherapy for VMs currently is sirolimus [13, 14] . Sirolimus is an mTOR inhibitor indicated for the prevention of organ rejection in patients older than 13 receiving a renal transplant [61] . The exact mechanism of action of sirolimus in VMs is not completely understood. The main target of sirolimus is mTOR complex 1 (mTORC1), which is a multiprotein signalling hub integrating signalling inputs from various sources such as growth factors, nutritional status and energy metabolism state [62] . However, on chronic exposure, sirolimus can also inhibit mTORC2, which is known to directly phosphorylate Ser473 residue of Akt, needed for its full activation [62, 63] . Sirolimus inhibited TIE2-VM-and PIK3CA-VM-induced Akt activation in transduced ECs in vitro and in vivo [6, 13] , and in mouse models, it diminished lesion growth, normalized SMC coverage and decreased EC proliferation [10, 13] . It is noteworthy that compared with alpelisib, sirolimus was not able to normalize all TIE2-VM and PIK3CA-VM EC phenotypic features in retrovirally transduced ECs, suggesting that not all pathogenic signalling pathways are blocked by sirolimus in VMs [6] .
Encouraged by the accumulated knowledge of pathogenic mechanisms of vascular malformations as outlined above, success in other PI3K/Akt/mTOR-signalling related diseases [64, 65] and positive experiences published as case reports [66] , large-scale prospective clinical trials testing sirolimus in the treatment of vascular malformations have been launched (Table S2 ). In the largest trial published so far, Adams et al. [14] enrolled 61 patients with heterogeneous complicated vascular malformations not adequately manageable with standard care and treated them with twice daily oral sirolimus. More than 80% of the patients who completed 6 or 12 cycles of continuous therapy (28 days per cycle) had a partial response defined by an improvement in radiological evaluation, quality of life and functional assessment. None of the patients had a complete response. Six patients who chose to pause sirolimus experienced a worsening of symptoms, and most patients continued sirolimus after the study. Similarly, in a prospective pilot cohort of six TIE2 and PIK3CA mutation-positive vascular malformation patients, improvement in quality of life, diminishment in pain, bleeding and oozing and a decrease in lesion volumes were reported [6, 13] . Although the data are limited, Adams et al. [14] suggested that sirolimus might be more effective if started in early childhood. This idea is supported by pre-clinical findings in mice where sirolimus was efficient in preventing growth of new lesions but less potent to diminish them once established [13] . It is noteworthy that in two other mTOR-related diseases -lymphangioleiomyomatosis and tuberous sclerosis -sirolimus was also able to halt the disease progression, but after ending the treatment, the disease progressed similarly to the untreated group [64, 65] . Two additional large clinical trials enrolling patients with [77] extensive vascular malformations are ongoing (Table S2 ) [67, 68] . Based on the published clinical data thus far, it seems evident that sirolimus can significantly ameliorate symptoms and diminish lesion volumes in patients with complicated vascular anomalies. Although reports on long-term efficacy are still lacking, sirolimus is unlikely to be completely curative in most patients [13, 14, 66, 69] . One intriguing yet unexplored possibility to boost treatment results could be the combination of sirolimus with MAPK inhibition. Sirolimus was not able to normalize all VM cellular phenotypes in vitro and in fact increased Erk1/2 phosphorylation, which could potentiate some of the cellular abnormalities [6, 12] . mTORC1 inhibition with sirolimus has been shown to induce negative feedback regulation leading to increased activation of PI3K, Akt, S6K1 and Erk pathways, likely limiting its efficacy in cancer and perhaps also in vascular anomalies [70] . Clinically approved Mek inhibitors (trametinib, cobimetinib) exist, which could be considered for repurposing to vascular anomalies as a combination therapy with sirolimus if first shown beneficial in preclinical models [71] .
Long-term or even lifelong medical treatment might be needed for VMs, meaning that the therapy must be welltolerated. It should also be applicable to paediatric patients. Targeting either PIK3CA or mTOR is expected to cause similar adverse effects (e.g. hyperglycaemia, hyperlipidaemia) as they predominantly inhibit the same PI3K/Akt/mTOR pathway [70] . Due to immunosuppression, sirolimus also increases susceptibility to infections and risk of malignancies [61] . In vascular anomaly patients, sirolimus has been generally relatively well-tolerated from adults to infants, even neonates [13, 14, 66, 69, 72, 73] (Table S2 ). Most commonly observed adverse effects have been bone marrow toxicity, hypertriglyceridaemia and infections. Most of the reported adverse effects have been mild and manageable with dose reduction. But occasionally persistent adverse effects, such as chronic mucositis, have led to cessation of treatment. In general, adverse effects seem as expected from previous sirolimus studies in its primary indication, and no new safety concerns have been raised. In contrast to sirolimus, only limited safety data exist on alpelisib, which has been used only as an investigational cancer drug in a limited number of adult patients [74] [75] [76] . A frequent adverse effect observed has been hyperglycaemia but usually as mild and requiring no action. Other common adverse effects include nausea, diarrhoea and skin reactions. In general, the safety profile has been deemed acceptable to continue further trials [75, 76] . In general, PI3K inhibitors have been found to cause significant adverse effects such as liver toxicity, rash, stomatitis and gastrointestinal symptoms, which have led to the termination of the development of many drug compounds of this class and especially the ones targeting multiple PI3K isoforms unselectively [56, 77] . Larger clinical trials are needed to better determine the safety profile of alpelisib. The crucial open question is whether paediatric patients tolerate it. It is possible that in VM patients, a lower dosage than in cancer could be used, since VMs are caused by the specific activation of the TIE2/PIK3CA pathway, in contrast to cancer where multiple oncogenic pathways are simultaneously activated. For superficial VMs, topical administration of the drugs might be an option for limiting systemic adverse effects [9] . Ideally, medical treatment would lead to sustained response without rebound growth, which would allow short-term or intermittent medication with limited adverse effects. Whether this can be achieved with PIK3CA inhibition remains to be tested.
Conclusion and Future Directions
Recent molecular, cellular and genetic studies have unravelled the cause of most VMs resulting from activating mutations in the TIE2/PI3K signalling pathway, and the first clinical studies indicate that molecular therapy of VMs can be effective. Although many candidate genes and proteins are found to be dysregulated, the exact pathogenic mechanisms downstream from mutated proteins are not clear however, and the first molecular treatment in the clinic using sirolimus has limitations. The genetic model for TIE2 gain-of-function mutationinduced VMs has not been reported, but it is plausible that similar to mosaic expression of Pik3ca H1047R , targeted TIE2 mutations would lead to VM formation in mice. This would be a valuable model to test possible differences in pathology and treatment response in PIK3CA-and TIE2-positive VMs, which may not be identical. As alpelisib but not sirolimus was able to completely restore phenotypes of mutant TIE2-and PIK3CA-transfected HUVECs [6] , it would be intriguing to directly compare the effects of these two compounds in an in vivo model of TIE2 and PIK3CA mutation-positive VMs. As VMs are due to somatic gain-of-function mutations in one allele, they are suitable candidates for gene therapy. The approach could be based on shRNAs for the silencing of expression of the mutated allele or silencing/correction of the mutated gene using genome editing tools. Development of such approaches for VM therapies, however, has not yet been published. The management of difficult-to-treat VMs has already been revolutionized by sirolimus. However, long-term sirolimus treatment may cause significant side effects, and in clinical studies thus far, it does not always reduce the volume of existing VM lesions. Mechanistic molecular data support the idea that PIK3CA inhibition would lead to a significantly better response if a suitable and safe molecule is found. Furthermore, in cultured HUVECs, sirolimus increases Erk1/2 activation, which potentiates cellular abnormalities in VM ECs [6, 12] , thus making further search for more specific inhibitors attractive and necessary for the development of VM-targeted molecular therapies. Currently, it seems unrealistic to expect that even most potent kinase inhibitors would lead to complete recovery of malformed tissue. However, they may prove to be important to stabilize difficult-to-treat VMs, and if combined with sclerotherapy or surgery, they may inhibit regrowth of malformed vasculature.
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